TY  - JOUR
AU  - Olry-de-Labry-Lima, Antonio 
AU  - Špacirova, Zuzana
AU  - Fenix-Caballero, Silvia
AU  - Hoces, Antonio Matas
AU  - Vegas, Adrian Sanchez
AU  - Aranzana, Manuel Cárdenas
AU  - Sierra-Sanchez, Jesus F
AU  - Diaz, Maria Del Carmen Martinez
AU  - Alegre Del Rey, Emilio Jesus
PY  - 2021
DO  - 10.1016/j.breast.2021.04.004
UR  - http://hdl.handle.net/10668/17627
T2  - Breast (Edinburgh, Scotland)
AB  - Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the...
LA  - en
PB  - Elsevier
KW  - Breast neoplasms
KW  - Cost-utility analysis
KW  - Healthcare costs
KW  - Poly(ADP-Ribose) polymerase inhibitors
KW  - Progression-free survival
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Breast neoplasms
KW  - Cost-benefit analysis
KW  - Female
KW  - Humans
KW  - Neoplasm recurrence, local
KW  - Phthalazines
KW  - Quality-adjusted life years
KW  - Spain
TI  - Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.
TY  - research article
VL  - 58
ER  -